Oppenheimer & Co. Inc. bought a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,088 shares of the biotechnology company’s stock, valued at approximately $469,000.
A number of other large investors also recently added to or reduced their stakes in AXON. American Century Companies Inc. raised its position in shares of Axon Enterprise by 103.8% in the 1st quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock valued at $853,000 after acquiring an additional 3,155 shares during the period. Private Advisor Group LLC raised its position in shares of Axon Enterprise by 40.3% in the 1st quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 994 shares during the period. Great West Life Assurance Co. Can raised its position in shares of Axon Enterprise by 12.3% in the 1st quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock valued at $5,247,000 after acquiring an additional 4,048 shares during the period. Raymond James Trust N.A. raised its position in shares of Axon Enterprise by 4.7% in the 1st quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock valued at $517,000 after acquiring an additional 168 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Axon Enterprise by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock valued at $32,545,000 after acquiring an additional 4,897 shares during the period. 76.52% of the stock is currently owned by institutional investors and hedge funds.
Axon Enterprise Price Performance
NASDAQ:AXON opened at $205.14 on Wednesday. Axon Enterprise, Inc. has a 1-year low of $109.31 and a 1-year high of $229.95. The company has a current ratio of 3.38, a quick ratio of 2.98 and a debt-to-equity ratio of 0.47. The firm has a fifty day simple moving average of $192.21 and a 200 day simple moving average of $203.68. The stock has a market capitalization of $15.34 billion, a PE ratio of 153.09 and a beta of 0.88.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last released its earnings results on Tuesday, August 8th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.47. Axon Enterprise had a net margin of 7.24% and a return on equity of 10.88%. The business had revenue of $374.61 million during the quarter, compared to analysts’ expectations of $347.53 million. On average, research analysts expect that Axon Enterprise, Inc. will post 1.96 EPS for the current fiscal year.
Insider Activity at Axon Enterprise
In related news, COO Joshua Isner sold 1,482 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $196.88, for a total value of $291,776.16. Following the completion of the transaction, the chief operating officer now directly owns 319,803 shares of the company’s stock, valued at $62,962,814.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Axon Enterprise news, insider Jeffrey C. Kunins sold 22,900 shares of Axon Enterprise stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $193.12, for a total transaction of $4,422,448.00. Following the completion of the transaction, the insider now directly owns 241,076 shares of the company’s stock, valued at $46,556,597.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Joshua Isner sold 1,482 shares of Axon Enterprise stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $196.88, for a total transaction of $291,776.16. Following the transaction, the chief operating officer now directly owns 319,803 shares of the company’s stock, valued at $62,962,814.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,265 shares of company stock valued at $9,905,331. 6.10% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
AXON has been the topic of a number of analyst reports. Morgan Stanley initiated coverage on shares of Axon Enterprise in a research report on Tuesday, August 22nd. They issued an “equal weight” rating and a $230.00 price target on the stock. StockNews.com began coverage on shares of Axon Enterprise in a report on Wednesday, August 23rd. They set a “hold” rating on the stock. Needham & Company LLC restated a “buy” rating and set a $240.00 target price on shares of Axon Enterprise in a report on Wednesday, August 9th. Barclays dropped their target price on shares of Axon Enterprise from $256.00 to $239.00 and set an “overweight” rating on the stock in a report on Wednesday, August 9th. Finally, Credit Suisse Group raised their target price on shares of Axon Enterprise from $300.00 to $309.00 in a report on Wednesday, May 10th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $244.73.
Check Out Our Latest Research Report on AXON
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
